The United Kingdom and the United States have hammered out a landmark bilateral deal that will guarantee no tariffs on UK pharmaceutical shipments entering the American market.
The Terms of the Accord
As part of the deal, the UK has committed to increase funding on drugs through the NHS. This commitment guarantees that import taxes on these key exports will be held at zero for a period of 36 months.
This development is in response to earlier statements to dramatically increase duties on patented drug imports, with potential rates mentioned up to double the cost.
"This arrangement between the United Kingdom bolsters the global environment for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement declared.
Economic Impact
Medicines constitute one of the the United Kingdom's biggest export categories to the US, which is by far the largest destination for large British pharmaceutical firms.
Export figures show that in the one-year period to the end of September, the UK exported drugs valued at billions to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This agreement secures employment, increases investment and facilitates the UK to become a worldwide center for life sciences," a government official stated.
Key British Pledges
The agreement includes several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%.
Broader Context
The pact follows a ongoing dispute between the drug companies and the ministers over spending levels and approval rates.
These tensions were heightened by claims that American customers were charged a premium for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
